Aclarion Shares Surge and Form Strategic Partnership with Alphatec Spine

By Chris Wack

Aclarion, a healthcare technology company, experienced a significant boost in its shares, increasing by 50% to reach $4.58. This surge follows the company's entrance into a strategic partnership agreement with Alphatec Spine, a wholly-owned subsidiary of Alphatec Holdings. The partnership solidifies a previously signed non-binding letter of intent between the two entities.

Despite this recent success, Aclarion's stock had hit its 52-week low of $2.75 on Friday and has seen a decline of 49% over the past year.

Through this collaboration, ATEC's AlphaInformatiX platform, which provides critical structural information, will be combined with Aclarion's Nociscan solution. Nociscan is equipped with biomarker data capable of identifying potentially painful discs. This integration will offer surgeons unprecedented access to comprehensive data on a single platform.

The ultimate goal is to improve clinical outcomes and reduce procedural costs for patients suffering from chronic low back pain.

This partnership encompasses multiple stages where Alphatec and Aclarion will join forces to identify key opinion leader surgeons who will evaluate the Nociscan technology. Beyond evaluation, both companies plan to co-market Nociscan in targeted markets. As part of their agreement, Aclarion will grant Alphatec exclusive distribution rights to include Nociscan as part of an integrated procedural solution. In return, Aclarion gains select access to Alphatec's esteemed surgeon network.